SEC Form 4 · accession 0001062993-18-003464
BIOSPECIFICS TECHNOLOGIES CORP · BSTC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas Wegman
Officer — President · Director
Period of report
Aug 14, 2018
Accepted (ET)
Aug 15, 2018 · 9:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875622
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.001 par valueF1 | Aug 14, 2018 | S | 15,987 | $51.207 | D | 320,340 | D | |
| Common Stock, $0.001 par valueF2 | Aug 15, 2018 | S | 7,921 | $50.0008 | D | 312,419 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents the weighted average sale price for total shares sold by the reporting person, including a range of prices from $50.00 to $54.11, inclusive.
- F2Represents the weighted average sale price for total shares sold by the reporting person, including a range of prices from $50.00 to $50.002, inclusive.